A new class of editor has improved delivery, durability, tunability, and safetyScience27 Jun 2024Vol 384, Issue 6703pp. 1407-1408AbstractAlthough the practice of molecular medicine has taken enormous strides in recent years—as attested to by a wave of approvals of antisense oligonucleotide (ASO) therapies as well as the first CRISPR-based therapy—neurodegenerative diseases, such as prion disease, Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease, remain a difficult challenge. To...